Sponsors (7)
The resolution raises visibility for rare-disease needs and reinforces research and regulatory pathways, but it provides no funding or immediate policy fixes and may shift focus toward long-term drug development over near-term access and affordability.
People with rare diseases and their families gain greater official visibility for their needs, which could inform and shape future policy and funding decisions.
Patients with rare diseases benefit from public recognition of FDA orphan drug programs and approvals because it highlights regulatory pathways that can speed development and eventual access to treatments.
Researchers and patients may gain stronger justification for continued or increased NIH research funding into rare-disease treatments due to formal acknowledgment of NIH support.
People with rare diseases and their families receive no immediate relief because the resolution does not provide funding or specific policy changes to address diagnostic, treatment, or cost challenges.
Emphasis on research and regulatory approvals risks shifting attention and resources toward long-term drug development rather than near-term needs like diagnosis, affordability, and access, disproportionately affecting low-income patients.
Highlighting FDA programs and approvals could create unrealistic public expectations for rapid treatment availability, despite most rare diseases lacking approved therapies.
Based on analysis of 2 sections of legislative text.
Records findings about rare diseases, highlights federal research and FDA approvals, and supports observance of Rare Disease Day each year on the last day of February.
Introduced February 27, 2025 by John A. Barrasso · Last progress February 27, 2025
Recognizes the scope and challenges of rare diseases in the United States, highlights federal research and FDA approvals, and supports the annual observance of Rare Disease Day on the last day of February. The resolution presents findings: a U.S. rare disease is defined as affecting fewer than 200,000 people; more than 30 million Americans live with one of over 10,000 rare diseases; many are serious or life‑threatening; children are a large share of patients; most rare diseases lack approved treatments; and federal agencies including FDA and NIH play ongoing roles in research and product approvals.